Literature DB >> 6614876

Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine.

J E Granato, B J Stern, A Ringel, A H Karim, A Krumholz, J Coyle, S Adler.   

Abstract

A patient with chronic schizophrenia treated with fluphenazine developed neuroleptic malignant syndrome, characterized by fever, obtundation, rigidity, and tremulousness. Hyperthermia and elevated serum creatine kinase were successfully corrected by parenteral treatment with dantrolene. Obtundation, rigidity, and tremulousness responded to high doses of bromocriptine.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6614876     DOI： 10.1002/ana.410140117

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  20 in total

Review 1.  Neuroleptic malignant syndrome.

Authors:  J Turk; B Lask
Journal:  Arch Dis Child       Date:  1991-01       Impact factor: 3.791

2.  Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism.

Authors:  T C Ryken; A N Merrell
Journal:  West J Med       Date:  1989-09

3.  Neuroleptic malignant syndrome.

Authors:  T H Lee; L M Tang
Journal:  J Neurol       Date:  1988-05       Impact factor: 4.849

4.  Muscle pathology in the neuroleptic malignant syndrome.

Authors:  D T Martin; M Swash
Journal:  J Neurol       Date:  1987-12       Impact factor: 4.849

Review 5.  Neuroleptic malignant syndrome.

Authors:  G A Chaimowitz; U Gomes; S S Maze
Journal:  CMAJ       Date:  1988-01-01       Impact factor: 8.262

6.  The syndrome of Karl Ludwig Kahlbaum.

Authors:  M P Barnes; M Saunders; T J Walls; I Saunders; C A Kirk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-09       Impact factor: 10.154

7.  A rapidly progressing lethal case of neuroleptic malignant syndrome.

Authors:  P Lenler-Petersen; B D Hansen; L Hasselstrøm
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

8.  Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.

Authors:  J Kornhuber; M Weller
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 9.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

10.  Dantrolene reduces the threshold and gain for shivering.

Authors:  Chun-Ming Lin; Sharma Neeru; Anthony G Doufas; Edwin Liem; Yunus Muneer Shah; Anupama Wadhwa; Rainer Lenhardt; Andrew Bjorksten; Akiko Taguchi; Barhara Kabon; Daniel I Sessler; Andrea Kurz
Journal:  Anesth Analg       Date:  2004-05       Impact factor: 5.108
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.